TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Earnings & Estimates
USA - New York Stock Exchange - NYSE:TAK - US8740602052 - ADR
14.315 USD
+0.09 (+0.67%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.027T 12.85% | 4.264T 5.87% | 4.582T 7.45% | 4.568T -0.30% | 4.595T 0.59% | 4.665T 1.53% | |
| EBITDA YoY % growth | 1.215T 7.68% | 1.159T -4.65% | 1.298T 12.05% | 1.222T -5.89% | 1.254T 2.65% | 1.272T 1.44% | |
| EBIT YoY % growth | 550.895B 0.99% | 430.787B -21.80% | 537.031B 24.66% | 401.98B -25.15% | 503.99B 25.38% | N/A | |
| Operating Margin | 13.68% | 10.10% | 11.72% | 8.80% | 10.97% | N/A | |
| EPS YoY % growth | 102.07 38.81% | 45.98 -54.95% | 34.13 -25.77% | 67.16 96.76% | 99.26 47.80% | 107.44 8.24% |
All data in JPY
| Q3 / 26 | Q4 / 26 | Q1 / 27 | |
|---|---|---|---|
| EPS Q2Q % growth | 20.18 171.98% | 2.43 107.44% | 31.32 -21.01% |
| Revenue Q2Q % growth | 1.197T 4.61% | 1.085T 3.02% | 1.155T 4.36% |
| EBITDA Q2Q % growth | 372.793B -41.68% | 176.897B -76.02% | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A |
All data in JPY
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2026 Q2Q % growth | -3.74 -112.87% | 17.05 | -20.78 | -121.92% |
| Q1 2026 Q2Q % growth | 39.65 30.79% | 28.54 | 11.11 | 38.94% |
| Q4 2025 Q2Q % growth | -32.63 -3,151.24% | -27.86 | -4.77 | -17.13% |
| Q3 2025 Q2Q % growth | 7.42 -78.01% | 12.70 | -5.28 | -41.58% |
| Q2 2025 Q2Q % growth | 29.03 287.55% | 16.54 | 12.49 | 75.50% |
| Q1 2025 Q2Q % growth | 30.31 5.56% | 22.07 | 8.24 | 37.34% |
| Q4 2024 Q2Q % growth | -1.00 -110.03% | 0.39 | -1.39 | -357.78% |
| Q3 2024 Q2Q % growth | 33.75 -11.88% | 14.37 | 19.38 | 134.84% |
| Q2 2024 Q2Q % growth | -15.48 -177.99% | 18.38 | -33.86 | -184.23% |
| Q1 2024 Q2Q % growth | 28.72 -15.35% | 34.89 | -6.17 | -17.69% |
| Q4 2023 Q2Q % growth | 10.00 388.22% | 6.78 | 3.22 | 47.57% |
| Q3 2023 Q2Q % growth | 38.30 107.24% | 37.59 | 0.71 | 1.89% |
| Q2 2023 Q2Q % growth | 19.85 35.93% | 19.29 | 0.56 | 2.91% |
| Q1 2023 Q2Q % growth | 33.92 -22.76% | 35.87 | -1.95 | -5.43% |
| Q4 2022 Q2Q % growth | -3.47 -105.51% | 3.01 | -6.48 | -215.36% |
| Q3 2022 Q2Q % growth | 18.48 -37.36% | 25.50 | -7.02 | -27.54% |
| Q2 2022 Q2Q % growth | 14.60 1,229.27% | 23.85 | -9.25 | -38.79% |
| Q1 2022 Q2Q % growth | 43.92 66.19% | 33.94 | 9.98 | 29.40% |
| Q4 2021 Q2Q % growth | 62.96 11,362.22% | 24.17 | 38.79 | 160.51% |
| Q3 2021 Q2Q % growth | 29.50 886.43% | 21.88 | 7.62 | 34.83% |
| Q2 2021 Q2Q % growth | 1.10 -93.64% | 16.42 | -15.32 | -93.31% |
| Q1 2021 Q2Q % growth | 26.43 498.57% | 8.09 | 18.34 | 226.72% |
| Q4 2020 Q2Q % growth | 0.55 101.14% | -53.03 | 53.58 | 101.04% |
| Q3 2020 Q2Q % growth | 2.99 -87.65% | -15.26 | 18.25 | 119.60% |
| Q2 2020 Q2Q % growth | 17.28 -43.93% | -23.50 | 40.78 | 173.52% |
| Q1 2020 Q2Q % growth | -6.63 -113.27% | -21.94 | 15.31 | 69.77% |
| Q4 2019 Q2Q % growth | -48.12 | -40.16 | -7.96 | -19.81% |
| Q2 2019 Q2Q % growth | 30.81 | 18.96 | 11.86 | 62.53% |
| Q1 2019 Q2Q % growth | 49.96 | 34.94 | 15.02 | 42.98% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2026 Q2Q % growth | 1.113T -5.38% | 1.184T | -71.525B | -6.04% |
| Q1 2026 Q2Q % growth | 1.107T -8.39% | 1.187T | -80.177B | -6.76% |
| Q4 2025 Q2Q % growth | 1.053T 0.24% | 1.076T | -22.558B | -2.10% |
| Q3 2025 Q2Q % growth | 1.144T 2.96% | 1.15T | -5.501B | -0.48% |
| Q2 2025 Q2Q % growth | 1.176T 12.75% | 1.106T | 70.201B | 6.35% |
| Q1 2025 Q2Q % growth | 1.208T 14.11% | 1.104T | 104.296B | 9.45% |
| Q4 2024 Q2Q % growth | 1.051T 9.91% | 916.958B | 133.911B | 14.60% |
| Q3 2024 Q2Q % growth | 1.111T 1.33% | 1.017T | 93.961B | 9.24% |
| Q2 2024 Q2Q % growth | 1.043T 4.07% | 1.009T | 33.671B | 3.34% |
| Q1 2024 Q2Q % growth | 1.059T 8.86% | 992.223B | 66.395B | 6.69% |
| Q4 2023 Q2Q % growth | 956.156B 9.49% | 966.415B | -10.259B | -1.06% |
| Q3 2023 Q2Q % growth | 1.097T 21.66% | 1.015T | 81.727B | 8.05% |
| Q2 2023 Q2Q % growth | 1.002T 18.64% | 962.035B | 40.272B | 4.19% |
| Q1 2023 Q2Q % growth | 972.465B 2.41% | 934.47B | 37.995B | 4.07% |
| Q4 2022 Q2Q % growth | 873.289B 13.37% | 847.458B | 25.831B | 3.05% |
| Q3 2022 Q2Q % growth | 901.294B 7.71% | 846.517B | 54.777B | 6.47% |
| Q2 2022 Q2Q % growth | 844.82B 7.08% | 825.266B | 19.554B | 2.37% |
| Q1 2022 Q2Q % growth | 949.603B 18.43% | 873.46B | 76.143B | 8.72% |
| Q4 2021 Q2Q % growth | 770.274B -0.19% | 791.881B | -21.607B | -2.73% |
| Q3 2021 Q2Q % growth | 836.753B -2.63% | 847.525B | -10.772B | -1.27% |
| Q2 2021 Q2Q % growth | 788.935B -2.73% | 840.261B | -51.326B | -6.11% |
| Q1 2021 Q2Q % growth | 801.85B -5.57% | 814.274B | -12.424B | -1.53% |
| Q4 2020 Q2Q % growth | 771.702B 7.60% | 802.131B | -30.429B | -3.79% |
| Q3 2020 Q2Q % growth | 859.317B 72.07% | 844.174B | 15.143B | 1.79% |
| Q2 2020 Q2Q % growth | 811.048B 88.28% | 822.735B | -11.687B | -1.42% |
| Q1 2020 Q2Q % growth | 849.121B 88.76% | 824.716B | 24.405B | 2.96% |
| Q4 2019 Q2Q % growth | 717.211B | 761.028B | -43.817B | -5.76% |
| Q2 2019 Q2Q % growth | 430.777B | 475.949B | -45.172B | -9.49% |
| Q1 2019 Q2Q % growth | 449.834B | 447.597B | 2.237B | 0.50% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 11.23% | -7.36% | -11.74% |
| Revenue | 1.51% | 1.48% | -0.31% | -0.69% |